AzTrials
AzTrials

Feeding Tube ComplicationAlbertNCT06772285

Albert Health App PEG Study

An observational study of Feeding Tube Complication, run by The Royal Wolverhampton Hospitals NHS Trust at 1 site in United Kingdom.

Not yet recruiting

Opening soon. The study is approved but enrolment has not started yet. Sites may already take enquiries.

Sites and contacts
Official record
Search all trials

Trial summary

Test an existing digital health app, called Albert Health, designed to support patients with a newly inserted feeding tube to use and manage their tube care, in a feasibility study. Read more about this study

Who is it for?
Ages 18 years and older
Conditions the study is for
Feeding Tube Complication
What is being tested?
Albert Health app
How many people
50 participants
Where
1 siteUnited Kingdom
Study dates
Feb 2026to Jun 2027
Phase
Observational
Are there results?
Not yet: the study is under way

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • All sexes
  • Adult, Older adult

Study population: All consecutive patients (adults) seen at New Cross Hospital or City Sandwell Hospital undergoing an elective percutaneous endoscopic gastrostomy will be approached. Participants may be recruited in the following partnerships: i) Primary app user is patient, who will be self-caring, willing to take part and able to consent ii) Co-primary app - patient and carer, both willing to take part and sharing the tube care and able to consent iii) Primary app user is carer providing most or all tube care, willing to take part, carer consent 1. Patient willing to consent - patient consent 2. Patient unable to consent- consultee consent There is no upper age limit for participation.

Who may be able to join

  • Person ≥18 and/or the carer of a person ≥18 having a PEG tube electively inserted; the participant or their supporting carer must be literate in English.
  • Written informed consent for study participation obtained from the patient or personal consultee (friend/family), with assent as appropriate by the patient, depending on the level of understanding.
  • Where a personal consultee is the primary participant (ie user of the app) it must be understood that data will be required and collected on the person they are supporting with the app and PEG tube.
  • Willingness to comply with all study requirements.
  • The participant or carer must have access to a smart phone or mobile device (such as a pad).

Who cannot join

  • Person being discharged to a nursing home
  • Both participant and carer are visually impaired.
  • Patient's whose PEG care will be solely provided by district nurses or professional health care workers
  • Patient has major surgery scheduled within 7 days of the PEG insertion date

Trial locations and contacts

1 site in 1 country. Contact the study team or a site near you to ask about taking part.

United Kingdom1 site
  • The Royal Wolverhampton NHS Trust

    Wolverhampton, WV10 0QP

Other trials in United Kingdom

About this study

Official title: Single Arm Feasibility Study of a Digital Health App to Support Adults With Managing a PEG Feeding Tube After Insertion

Test an existing digital health app, called Albert Health, designed to support patients with a newly inserted feeding tube to use and manage their tube care, in a feasibility study. The feasibility study will evaluate the acceptability, usability and accessibility of the app in preparation for a randomised controlled trial.

Read the detailed description

Seven thousand people have a feeding tube inserted directly into the stomach or bowel in the UK each year for the purposes of giving fluid, food or medication via the tube instead of orally. Over one third will experience a complication in the first 12 months after insertion, half of whom will experience it in the first 30 days. For the majority of people pain, infection and leaking are the commonest early complications; for most, these complications are minor and do not require intervention. But they also mimic the symptoms of more serious complications, making it an anxious time for patients and carers and hard for them to discern if and what level of help they need. Six percent of all people with a PEG will have to spend time in hospital having the problem investigated or managed and 5% will die in the first 30 days after a tube insertion, predominantly from procedure related complications.

Currently the insertion of a feeding tube is an invasive process, undertaken on both inpatients and outpatients for a variety of medical reasons including the need for cancer treatment and for medium- or long-term neurological conditions and/or severe learning disabilities (LD) affecting swallowing, often with multiple comorbidities. All these populations have a higher mortality, and in this situation are often further disadvantaged by their illness affecting their ability to communicate. The LD population in particular suffer from inequities of healthcare outcomes and are underrepresented in the physical health research arena.

After the procedure and discharge people/carers are supported by a multidisciplinary team, including a community nurse, to help them use their tube and the associated equipment and information to troubleshoot tube problems in accordance with NICE guidance. This includes use of a pharma-owned digital app for simple device guidance around the electronic equipment. Some areas in the UK have nutrition nurse specialist teams that can be contacted during weekdays for support.

Should a significant complication occur out of normal working hours, people with feeding tubes often end up attending the emergency department as they do not have access to support or advice. This is common as people tend to use their tubes in the evening.

Patients and family in the investigators Patient Advisory Group (PAG) reported it was an 'overwhelming' and 'frightening' experience living with a PEG tube in the first few weeks. The group reported it was hard to access support as an outpatient and slow response to support requests led to unnecessary admissions or prolonged hospital stays. There was a perception of a lack of transition of care between the hospital and community setting and better or repeated information earlier in the process could reduce the learning curve of how to manage their feeding tubes. The group described that, currently provided, written information in the form of leaflets was perceived as "very daunting" and a "bit scary at first". The group suggested the investigators focus on improving the support around implementing the training they received in hospital and access to early advice. All patients reported they used the pharma company apps and would be willing to use an app to support them or ease the transition phase from secondary to community care.

In the event people with feeding tubes attend the emergency department, there is often not a need for admission, and they can be managed with simple advice or measures, and these are preventable attendances. Where rapid care is required to prevent admission, delays to care can result in avoidable admissions and our PPI group expressed frustration that this was occurring when it could be prevented with better access to advice or support.

Albert Health is a digital app used in Turkey, where it is nationally commissioned to support >6000 professional carers with enteral feeding tubes to manage simple problems for themselves and know when to access help. In the UK over half of our patients manage their feeding tubes themselves or within their nuclear families.

Therefore, the investigators have an underserved population identifying a specific need for support, who suffer healthcare inequalities and have healthcare accessibility challenges, but who the investigators know will, and do, use app technology for tube management. The investigators propose to employ a successful and internationally utilised app, with content co-designed and created with PPI to offer that additional support and advice to improve the health and wellbeing of our people with newly inserted feeding tubes. A secondary effect will be reducing the burden on the healthcare system and tackling healthcare inequalities in a multi-morbid population.

The investigators have created English language versions of the content that adheres to UK guidance, that is accessible by voice access and by typing and touch screen. The content and 'nudges' have been co-created with patients and carers to be suitable for patients themselves and their familial carers and both content and nudges are tube-type specific to offer them a personalised experience. The app uses nudge technology to highlight key dates after tube insertion for specific care and support and answers commonly asked questions, with supportive subtitled video content on using the tube, looking after the tube and dealing with simple problems. The app also allows users to set reminders to help maintain good care of the tube over the longer term, which will help prevent longer-term serious complications.

This feasibility study would test the app in the UK and understand if the adapted version works as intended as an intervention, if it is acceptable to patients, if it is useable and accessible, and if this population would be readily recruited to a larger research study. Answering these questions would determine if the app would be suitable to be tested in a randomised controlled trial against standard care and collate data to define the parameters of that future study. This clinical population are often disabled, and this will allow us to focus on if the accessibility adaptations are suitable and if it is usable in the intended population and if recruitment amongst this population to support a larger study is feasible.

Percutaneous endoscopic gastrostomy (PEG), a technique first described in 1980 provides long-term enteral nutrition access in patients with a functional gastrointestinal tract and impaired swallowing. PEGs are better tolerated and associated with better nutritional outcomes and fewer complications than nasogastric tubes and therefore guidelines recommend PEG for prolonged enteral supplementation.

PEG insertion is invasive; complications can include bowel perforation, bleeding, infection and tube displacement. The 2004 National Confidential Enquiry into Patient Outcome and Death report reviewed all UK deaths associated with PEG procedure between April 2002 and March 2003. The report found that 20% of PEGs were futile or not indicated, 40% had concurrent chest infection and 43% of deaths occurred within 7 days of the procedures. A follow up population-based study in the UK has demonstrated improved patient outcomes at a national level with a reduction in all-cause 30 day mortality of 60% following PEG insertion between 2007 and 2019.

A recent UK national report highlighted substantial variation in 30-day mortality rates following PEG insertion. One possible reason suggested was variation in nutrition support team provision across the UK, 16.7% of providers have no nutrition support and 25% no dedicated nutrition nurse specialist.

Experiencing complications is common. In a single-centre UK study between 2016-2018, 80% of PEG recipients were cared for in their own home and 16.7% experienced a complication in the first 30 days, with over 35% having a complication within 12 months. The most common complication was pain, for which home-cared patients were more likely to seek medical attention than patients from nursing homes. In a study by Barret et al 2021 identified that an Emergency Department attendance for a PEG tube problem cost an average of $1061 per person manifested in days in hospital and procedural costs, as well as patient morbidity with over half of the ED attendances resolved at the bedside.

Qualitative studies on patients experience with a PEG tube identified challenges adapting both physically and psychosocially. Discomfort was commonly described, and much effort and time was spent managing tube problems, often without support from knowledgeable healthcare professionals. Additionally, people with enteral tubes needed considerable support from knowledgeable, responsive healthcare professionals during the weeks following initial placement of the enteral tube, leading them to recommend 24-hour services designed in partnership with patients to support, reduce burden, negative experience, waste and hospital admissions.

Therefore, the investigators have a predominantly home-based population with enteral tubes, likely to experience pain and challenges, especially shortly after PEG insertion, that would prompt them to seek medical reassurance and support without requiring an inpatient admission. This occurs in a country with a geographically variable hospital-based nutrition support service and in a disease-specific population familiar with app-based technology as part of the standard care in the UK.

The Albert Health app aims to meet that need using an advanced digital healthcare app that is already successful for this purpose, utilised and nationally commissioned in an EU country. It has been redesigned in partnership with UK patients, public and healthcare staff to offer practical support, reassurance, signposting, education and behavioural modification to reduce negative experience and burden on patients at home with an enteral tube and ultimately reduce attendances at hospital.

Being tested
Albert Health app
Keywords
Digital health app, Management, PEG, Feeding tube, Insertion, Albert Health, PEG insertion

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Albert Health appOther

    Test an existing digital health app, called Albert Health, designed to support patients with a newly inserted feeding tube to use and manage their tube care, in a feasibility study.

Study groups in NCT06772285
Study groupRoleWhat they receive
PEG tube electively insertedAdults ≥18 years and/or the carer of a person ≥18 having a PEG tube electively inserted
Receives: Other: Albert Health app

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Evaluate the acceptability of the app intervention to users

    Evaluate the acceptability of the app intervention to users ; interviews, MARS day 14 and 28

    Measured: Day 14 and 28

  2. Evaluate the useability and interaction with the app by users

    Evaluate the useability and interaction with the app by users ; interviews, internal app measures

    Measured: 18 months

  3. Evaluate the accessibility of the app to users

    Evaluate the accessibility of the app to users ; interviews

    Measured: 18 months

  4. Evaluate the accessibility of the app to users

    Evaluate the accessibility of the app to users ; satisfaction scores (SUS subcale)

    Measured: 18 months

  5. Evaluate the accessibility of the app to users

    Evaluate the accessibility of the app to users ; MAUQ-E subscales

    Measured: 18 months

  6. Evaluate the useability and interaction with the app by users

    Evaluate the useability and interaction with the app by users ; System Usability Scale SUS

    Measured: Day 21

  7. Evaluate the useability and interaction with the app by users

    Evaluate the useability and interaction with the app by users ; MAUQ-E

    Measured: Day 21

  8. Evaluate ability to recruit this specific patient and carer population into a research trial

    Evaluate ability to recruit this specific patient and carer population into a research trial ; recruitment rate

    Measured: 18 months

  9. Evaluate ability to recruit this specific patient and carer population into a research trial

    Evaluate ability to recruit this specific patient and carer population into a research trial ; numbers approached versus numbers recruited

    Measured: 18 months

  10. Evaluate ability to recruit this specific patient and carer population into a research trial

    Evaluate ability to recruit this specific patient and carer population into a research trial ; percentage who complete the study period

    Measured: 18 months

  11. Evaluate ability to recruit this specific patient and carer population into a research trial

    Evaluate ability to recruit this specific patient and carer population into a research trial ; questionnaire completion rates

    Measured: 18 months

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted13 Jan 2025
  2. Study startFeb 2026 (estimated)
  3. Primary completionJun 2027 (estimated)
  4. Study completionJun 2027 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Observational
Observational model
Cohort
Time perspective
Prospective
Enrolment
50 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT06772285
Sponsor's protocol ID
2024GAS132
Acronym
Albert
Status last verified
Jan 2026
First submitted
2 Jan 2025
Last updated
15 Jan 2026
Results posted
No
FDA-regulated drug
No
FDA-regulated device
No

Questions about this trial

What is this clinical trial studying?

An observational study of Feeding Tube Complication, run by The Royal Wolverhampton Hospitals NHS Trust at 1 site in United Kingdom.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 5 inclusion and 4 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: opening soon, as of the sponsor's last update on 15 Jan 2026. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in United Kingdom. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

This study is still under way. Results are not available in the source record yet.

How can a doctor refer a patient or contact the research team?

Contact Helen Steed (01902 694009, helen.steed@nhs.net), or a site near the patient. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Evaluate the acceptability of the app intervention to users (time frame: Day 14 and 28). The study lists 11 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 15 Jan 2026.

Free account

Keep searching with a free account

You’ve used your 3 free searches for this session. Log in or create a free AzTrials account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in